Belgian Amyloidosis Biobank and Patient Registry at UZ Leuven

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The program will prospectively collect human body material (HBM) and linked clinical data from adults with suspected or confirmed amyloidosis to create a GDPR-compliant biobank and database. Samples and data will include newly diagnosed patients and those with relapse for the prospective collection, and will capture disease presentation, treatment plans, responses, and survival. The initiative is run by UZ Leuven in collaboration with VIB and aims to support multi-disciplinary research across participating centers. Material and data will be stored for future scientific studies to enable biomarker discovery and improved understanding of amyloidosis subtypes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provide consent and sign informed consent form
* Age 18 years or older
* Diagnosis of amyloidosis (suspected or confirmed, any subtypes)
* For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis)

Exclusion Criteria:

* Not willing to sign informed consent
* Not able to sign informed consent

Where it's running

• UZ Leuven Gasthuisberg - hematology
  Leuven, Belgium Recruiting
• UZ Leuven Gasthuisberg - cardiology
  Leuven, Belgium Recruiting

Study contacts

• Principal investigator: Michel Delforge — UZ Leuven Gasthuisberg
• Study coordinator: Michel Delforge
• Email: michel.delforge@uzleuven.be
• Phone: +32 16 346880

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with systemic amyloidosis

  This study is collecting information from patients with systemic amyloidosis to better understand the disease and how different treatments work over time.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT06887283

• Evaluation of heart health in patients with ATTR amyloidosis on tafamidis treatment

  This study looks at how tafamidis treatment affects heart health in patients with ATTR amyloidosis by checking their heart rhythm and other health needs every six months.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT06251778

• Optimizing first-line treatment for AL amyloidosis with specific genetic markers

  This study is testing a new treatment plan for people with AL amyloidosis who have a specific genetic marker to see if it helps them respond better and faster to their first-line therapy.

  Recruiting at 7 sites Peking University People's Hospital · Beijing, Beijing Municipality and 6 other locations · NCT06192979

• Testing Belantamab Mafodotin for AL Amyloidosis

  This study is testing a new drug called Belantamab Mafodotin to see if it can safely help people with relapsed or hard-to-treat AL Amyloidosis feel better.

  Recruiting at 2 sites Phase 1/2 University of Texas Southwestern Medical Center · Nashville, Tennessee and 2 other locations · NCT05145816

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Detecting cardiac amyloidosis in people with severe aortic valve narrowing

  This study tests non-invasively whether imaging tests can find heart amyloidosis in patients with severe aortic stenosis who are being evaluated for valve replacement.

  Recruiting University Hospital Tuebingen · Tübingen · NCT07752732

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.